Sun Pharmaceutical’s GL0034 study reveals promising obesity treatment outcomes
Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults. The findings, presented at the 84th American ... Read More
Sun Pharma’s GL0034 yields promising results in two Phase 1 trials
Sun Pharmaceutical Industries has unveiled positive results from two Phase 1 studies assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of GL0034, a novel long-acting GLP-1 ... Read More